Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754221 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT00754221 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 390 participants.
The verdict
NCT00754221, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
This is a study to investigate the long-term safety and effectiveness \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.
Interventions
- DRUG [S,S]-Reboxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754221
The ClinicalTrials.gov registry entry for NCT00754221 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [S,S]-Reboxetine is the first listed.
NCT00754221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00754221 about?
NCT00754221 is a clinical study titled "Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia". This is a study to investigate the long-term safety and effectiveness \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.
What is the current status of trial NCT00754221?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2008-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00754221?
The interventions under investigation include: [S,S]-Reboxetine (DRUG).
Who is sponsoring clinical trial NCT00754221?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.